UPDATE: Exelixis (EXEL) Falls to Session Low on Cabozantinib and Opdivo Data

September 28, 2016 11:46 AM EDT
Get Alerts EXEL Hot Sheet
Price: $18.09 -1.09%

Rating Summary:
    6 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 17 | New: 10
Trade EXEL Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

(Updated - September 28, 2016 11:57 AM, 12.56 PM EDT)

Exelixis (NASDAQ: EXEL) shares dropped Wednesday, falling 20%. The decline was tied to concerns about cabozantinib and Opdivo data and a numerically lower objected response rate vs other drugs combinations in testing.

According to Bloomberg, Stifel analyst Stephen Willey said data precludes comparisons.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Momentum Movers, Trader Talk

Related Entities


Add Your Comment